Tumor necrosis factor — Drug Target

All drugs that target Tumor necrosis factor — marketed and clinical-stage. Includes 4 drug classes acting on this target.

Drug classes

Tumor Necrosis Factor Blocker [EPC] · Guanylate Cyclase-C Agonist [EPC] · thalidomide · biologic

Marketed (14)

• Remicade · Johnson & Johnson · Tumor Necrosis Factor Blocker [EPC] · Oncology
  Remicade works by binding to and neutralizing tumor necrosis factor, a protein that promotes inflammation and tissue damage.
• Enbrel · Immunex · Tumor Necrosis Factor Blocker [EPC] · Oncology
  Enbrel works by binding to tumor necrosis factor, a protein that promotes inflammation, thereby reducing inflammation and alleviating symptoms.
• Humira · Sohag University · Oncology
• Enbrel · LG Life Sciences · Oncology
• Remicade · Shanghai Biomabs Pharmaceutical Co., Ltd. · Oncology
• CYLTEZO · BOEHRINGER INGELHEIM · Oncology
• Trulance · Salix · Guanylate Cyclase-C Agonist [EPC] · Oncology
  Trulance works by stimulating the guanylate cyclase-C receptor to increase fluid secretion in the intestines.
• IXIFI · PFIZER INC · Oncology
• Simponi · Alvotech Swiss AG · Oncology
• Simponi · Centocor Ortho Biotech Inc · Tumor Necrosis Factor Blocker [EPC] · Oncology
  Simponi works by binding to tumor necrosis factor, preventing it from interacting with its receptors and thereby reducing inflammation.
• Cimzia · University of Washington · Oncology
• Nanozora · Taisho Pharmaceutical Co., Ltd. · Oncology
• Thalomid · Bristol-Myers Squibb · thalidomide · Oncology
  Thalomid works by inhibiting the production of tumor necrosis factor, a protein that promotes inflammation and tumor growth.
• tumor necrosis factor inhibitors (TNFi) · Pfizer · biologic · Oncology